
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

SCHEDULE 14D-9

**Solicitation/Recommendation Statement
Under Section 14(d)(4) of the Securities Exchange Act of 1934**

CADENCE PHARMACEUTICALS, INC.
(Name of Subject Company)

CADENCE PHARMACEUTICALS, INC.
(Name of Person Filing Statement)

Common Stock, par value \$0.0001 per share
(Title of Class of Securities)

12738T100
(CUSIP Number of Class of Securities)

**Theodore R. Schroeder
President and Chief Executive Officer
Cadence Pharmaceuticals, Inc.
12481 High Bluff Drive, Suite 200
San Diego, California 92130
(858) 436-1400**

(Name, address and telephone number of person authorized to receive
notices and communications on behalf of the persons filing statement)

With copies to:

**Charles K. Ruck
Cheston J. Larson
Matthew T. Bush
Latham & Watkins LLP
12636 High Bluff Drive, Suite 400
San Diego, California 92130
(858) 523-5400**

Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

The information set forth under Items 1.01 and 8.01 of the Current Report on Form 8-K filed by Cadence Pharmaceuticals, Inc. on February 11, 2014 (including all exhibits attached thereto and incorporated therein by reference), is incorporated herein by reference.